What You Should Know:
– Blue Earth Diagnostics, a Bracco company and leader in innovative PET radiopharmaceuticals, announced a data-sharing agreement with Siemens Healthineers.
– This collaboration focuses on anonymized data from Blue Earth’s Phase 3 LIGHTHOUSE trial of POSLUMA® (flotufolastat F 18) injection, used for imaging prostate cancer.
Optimizing AI for Improved Prostate Cancer Detection
Siemens Healthineers will leverage the anonymized clinical data and images from the LIGHTHOUSE trial to enhance its AI-powered analytics for prostate cancer. This will lead to:
- More Precise Image Quantification: AI algorithms will be refined to provide more accurate measurement of prostate cancer lesions detected by POSLUMA PET scans.
- Enhanced Image Interpretation: Advanced AI tools will be developed to assist healthcare professionals in interpreting PET scans, potentially leading to earlier and more precise diagnoses.
About POSLUMA®
POSLUMA, previously known as 18F-rhPSMA-7.3, is a recently approved radiopharmaceutical for PET imaging of prostate cancer. It targets the Prostate-Specific Membrane Antigen (PSMA), a protein often overexpressed by prostate cancer cells. This targeted approach allows for more effective detection of prostate cancer compared to traditional imaging methods.
Details of the LIGHTHOUSE Trial
The LIGHTHOUSE trial was a large-scale clinical study involving over 350 men with newly diagnosed prostate cancer. It evaluated the safety and effectiveness of POSLUMA PET imaging in identifying prostate cancer lesions.
Blue Earth Diagnostics: A Leader in rhPSMA Technology
Blue Earth Diagnostics holds exclusive worldwide rights to the radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) diagnostic imaging technology. This technology has the potential to revolutionize prostate cancer diagnosis and treatment.
“Blue Earth Diagnostics is committed to helping men with prostate cancer across the care continuum, and we recognize the importance of AI in advancing healthcare,” said David Gauden, D.Phil., Chief Executive Officer, Blue Earth Diagnostics. “AI-based algorithms have the potential to streamline the PET/CT analytical workflow for hospitals and imaging centers by efficiently providing physicians with information critical to patient management and care. Blue Earth Diagnostics has a long-standing relationship with Siemens Healthineers, a leading medical technology company pioneering breakthroughs in healthcare.”
